SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Maia Ana Teresa) "

Sökning: WFRF:(Maia Ana Teresa)

  • Resultat 1-5 av 5
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Bousquet, J. Jean, et al. (författare)
  • Next-generation ARIA care pathways for rhinitis and asthma a model for multimorbid chronic diseases
  • 2019
  • Ingår i: Clinical and Translational Allergy. - BMC. - 2045-7022 .- 2045-7022. ; 9
  • Forskningsöversikt (övrigt vetenskapligt)abstract
    • Background: In all societies, the burden and cost of allergic and chronic respiratory diseases are increasing rapidly. Most economies are struggling to deliver modern health care effectively. There is a need to support the transformation of the health care system into integrated care with organizational health literacy.Main body: As an example for chronic disease care, MASK (Mobile Airways Sentinel NetworK), a new project of the ARIA (Allergic Rhinitis and its Impact on Asthma) initiative, and POLLAR (Impact of Air POLLution on Asthma and Rhinitis, EIT Health), in collaboration with professional and patient organizations in the field of allergy and airway diseases, are proposing real-life ICPs centred around the patient with rhinitis, and using mHealth to monitor environmental exposure. Three aspects of care pathways are being developed: (i) Patient participation, health literacy and self-care through technology-assisted "patient activation", (ii) Implementation of care pathways by pharmacists and (iii) Next-generation guidelines assessing the recommendations of GRADE guidelines in rhinitis and asthma using real-world evidence (RWE) obtained through mobile technology. The EU and global political agendas are of great importance in supporting the digital transformation of health and care, and MASK has been recognized by DG Sante as a Good Practice in the field of digitally-enabled, integrated, person-centred care.Conclusion: In 20 years, ARIA has considerably evolved from the first multimorbidity guideline in respiratory diseases to the digital transformation of health and care with a strong political involvement.
2.
  • Peterlongo, Paolo, et al. (författare)
  • Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
  • 2015
  • Ingår i: Cancer Epidemiology, Biomarkers and Prevention. - American Association for Cancer Research. - 1055-9965. ; 24:1, s. 308-316
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: BRCA1 and BRCA2 mutation carriers are at substantially increased risk for developing breast and ovarian cancer. The incomplete penetrance coupled with the variable age at diagnosis in carriers of the same mutation suggests the existence of genetic and nongenetic modifying factors. In this study, we evaluated the putative role of variants in many candidate modifier genes. Methods: Genotyping data from 15,252 BRCA1 and 8,211 BRCA2 mutation carriers, for known variants (n = 3,248) located within or around 445 candidate genes, were available through the iCOGS custom-designed array. Breast and ovarian cancer association analysis was performed within a retrospective cohort approach. Results: The observed P values of association ranged between 0.005 and 1.000. None of the variants was significantly associated with breast or ovarian cancer risk in either BRCA1 or BRCA2 mutation carriers, after multiple testing adjustments. Conclusion: There is little evidence that any of the evaluated candidate variants act as modifiers of breast and/or ovarian cancer risk in BRCA1 or BRCA2 mutation carriers. Impact: Genome-wide association studies have been more successful at identifying genetic modifiers of BRCA1/2 penetrance than candidate gene studies.
  •  
3.
  • Coelho, Teresa, et al. (författare)
  • Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy
  • 2013
  • Ingår i: Journal of Neurology. - Springer Berlin/Heidelberg. - 0340-5354. ; 260:11, s. 2802-2814
  • Tidskriftsartikel (refereegranskat)abstract
    • Tafamidis, a transthyretin (TTR) kinetic stabilizer, delayed neuropathic progression in patients with Val30Met TTR familial amyloid polyneuropathy (TTR-FAP) in an 18-month randomized controlled trial (study Fx-005). This 12-month, open-label extension study evaluated the long-term safety, tolerability, and efficacy of tafamidis 20 mg once daily in 86 patients who earlier received blinded treatment with tafamidis or placebo. Efficacy measures included the Neuropathy Impairment Score in the Lower Limbs (NIS-LL), Norfolk Quality of Life-Diabetic Neuropathy total quality of life (TQOL) score, and changes in neurologic function and nutritional status. We quantified the monthly rates of change in efficacy measures, and TTR stabilization, and monitored adverse events (AEs). Patients who continued on tafamidis had stable rates of change in NIS-LL (from 0.08 to 0.11/month; p = 0.60) and TQOL (from -0.03 to 0.25; p = 0.16). In patients switched from placebo, the monthly rate of change in NIS-LL declined (from 0.34 to 0.16/month; p = 0.01), as did TQOL score (from 0.61 to -0.16; p < 0.001). Patients treated with tafamidis for 30 months had 55.9 % greater preservation of neurologic function as measured by the NIS-LL than patients in whom tafamidis was initiated later. Plasma TTR was stabilized in 94.1 % of patients treated with tafamidis for 30 months. AEs were similar between groups; no patients discontinued because of an AE. Long-term tafamidis was well tolerated, with the reduced rate of neurologic deterioration sustained over 30 months. Tafamidis also slowed neurologic impairment in patients previously given placebo, but treatment benefits were greater when tafamidis was begun earlier.
  •  
4.
  • Coelho, Teresa, et al. (författare)
  • Tafamidis for transthyretin familial amyloid polyneuropathy : A randomized, controlled trial
  • 2012
  • Ingår i: Neurology. - Philadelphia : Lippincott Williams & Wilkins. - 0028-3878. ; 79:8, s. 785-792
  • Tidskriftsartikel (refereegranskat)abstract
    • Objectives: To evaluate the efficacy and safety of 18 months of tafamidis treatment in patients with early-stage V30M transthyretin familial amyloid polyneuropathy (TTR-FAP). Methods: In this randomized, double-blind trial, patients received tafamidis 20 mg QD or placebo. Coprimary endpoints were the Neuropathy Impairment Score-Lower Limbs (NIS-LL) responder analysis (<2-point worsening) and treatment-group difference in the mean change from baseline in Norfolk Quality of Life-Diabetic Neuropathy total score (TQOL) in the intent-to-treat (ITT) population (n = 125). These endpoints were also evaluated in the efficacy-evaluable (EE; n = 87) population. Secondary endpoints, including changes in neurologic function, nutritional status, and TTR stabilization, were analyzed in the ITT population. Results: There was a higher-than-anticipated liver transplantation dropout rate. No differences were observed between the tafamidis and placebo groups for the coprimary endpoints, NIS-LL responder analysis (45.3% vs 29.5% responders; p = 0.068) and change in TQOL (2.0 vs 7.2; p = 0.116) in the ITT population. In the EE population, significantly more tafamidis patients than placebo patients were NIS-LL responders (60.0% vs 38.1%; p = 0.041), and tafamidis patients had better-preserved TQOL (0.1 vs 8.9; p = 0.045). Significant differences in most secondary endpoints favored tafamidis. TTR was stabilized in 98% of tafamidis and 0% of placebo patients (p < 0.0001). Adverse events were similar between groups. Conclusions: Although the coprimary endpoints were not met in the ITT population, tafamidis was associated with no trend toward more NIS-LL responders and a significant reduction in worsening of most neurologic variables, supporting the hypothesis that preventing TTR dissociation can delay peripheral neurologic impairment. Classification of evidence: This study provides Class II evidence that 20 mg tafamidis QD was associated with no difference in clinical progression in patients with TTR-FAP, as measured by the NIS-LL and the Norfolk QOL-DN score. Secondary outcomes demonstrated a significant delay in peripheral neurologic impairment with tafamidis, which was well tolerated over 18 months. Neurology (R) 2012;79:785-792
  •  
5.
  • Maia, Ana-Teresa, et al. (författare)
  • Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers
  • 2012
  • Ingår i: Breast Cancer Research. - BioMed Central. - 1465-5411. ; 14:2
  • Tidskriftsartikel (refereegranskat)abstract
    • INTRODUCTION: Cis-acting regulatory single nucleotide polymorphisms (SNPs) at specific loci may modulate penetrance of germline mutations at the same loci by introducing different levels of expression of the wild-type allele. We have previously reported that BRCA2 shows differential allelic expression and we hypothesize that the known variable penetrance of BRCA2 mutations might be associated with this mechanism.METHODS: We combined haplotype analysis and differential allelic expression of BRCA2 in breast tissue to identify expression haplotypes and candidate cis-regulatory variants. These candidate variants underwent selection based on in silico predictions for regulatory potential and disruption of transcription factor binding, and were functionally analyzed in vitro and in vivo in normal and breast cancer cell lines. SNPs tagging the expression haplotypes were correlated with the total expression of several genes in breast tissue measured by Taqman and microarray technologies. The effect of the expression haplotypes on breast cancer risk in BRCA2 mutation carriers was investigated in 2,754 carriers.RESULTS: We identified common haplotypes associated with differences in the levels of BRCA2 expression in human breast cells. We characterized three cis-regulatory SNPs located at the promoter and two intronic regulatory elements which affect the binding of the transcription factors C/EBPα, HMGA1, D-binding protein (DBP) and ZF5. We showed that the expression haplotypes also correlated with changes in the expression of other genes in normal breast. Furthermore, there was suggestive evidence that the minor allele of SNP rs4942440, which is associated with higher BRCA2 expression, is also associated with a reduced risk of breast cancer (per-allele hazard ratio (HR) = 0.85, 95% confidence interval (CI) = 0.72 to 1.00, P-trend = 0.048).CONCLUSIONS: Our work provides further insights into the role of cis-regulatory variation in the penetrance of disease-causing mutations. We identified small-effect genetic variants associated with allelic expression differences in BRCA2 which could possibly affect the risk in mutation carriers through altering expression levels of the wild-type allele.
Skapa referenser, mejla, bekava och länka
  • Resultat 1-5 av 5
Åtkomst
fritt online (2)
Typ av publikation
tidskriftsartikel (4)
forskningsöversikt (1)
Typ av innehåll
refereegranskat (4)
övrigt vetenskapligt (1)
Författare/redaktör
Nevanlinna, Heli (2)
Suhr, Ole B., (2)
Coelho, Teresa (2)
Eccles, Diana (2)
Chenevix-Trench, Geo ... (2)
Easton, Douglas F. (2)
visa fler...
Plante-Bordeneuve, V ... (2)
Bjermer, Leif, (1)
Aittomäki, Kristiina (1)
Aittomaki, K (1)
Chang-Claude, Jenny (1)
Garcia-Aymerich, Jud ... (1)
Picard, Robert, (1)
Eeles, Rosalind A (1)
Cybulski, Cezary (1)
Teixeira, Manuel R (1)
Neuhausen, Susan L (1)
Campistol, Josep M. (1)
Conceicao, Isabel (1)
Walker, Samantha (1)
Agache, Ioana, (1)
Annesi-Maesano, Isab ... (1)
Yorgancioglu, Arzu, (1)
Jutel, Marek, (1)
Pfaar, Oliver, (1)
Spranger, Otto, (1)
Brunet, Joan, (1)
Gamkrelidze, Amiran (1)
Platte, Radka (1)
Evans, D. Gareth (1)
Buys, Saundra S. (1)
Southey, Melissa C. (1)
Spurdle, Amanda B. (1)
Benitez, Javier (1)
Schmutzler, Rita K. (1)
Meindl, Alfons (1)
Hamann, Ute (1)
Wang-Gohrke, Shan (1)
Wang, Xianshu (1)
Andrulis, Irene L. (1)
Beesley, Jonathan (1)
Ponder, Bruce A. J. (1)
Pharoah, Paul D. P. (1)
Askmalm Stenmark, Ma ... (1)
Borg, Åke, (1)
Caldas, Carlos (1)
Rudolph, Anja (1)
Wickman, Magnus, (1)
Antó, Josep M (1)
visa färre...
Lärosäte
Umeå universitet (2)
Lunds universitet (2)
Uppsala universitet (2)
Karolinska Institutet (2)
Göteborgs universitet (1)
Linköpings universitet (1)
Språk
Engelska (5)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (5)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy